Right now, the only oral GLP-1 medication available is Rybelsus, an oral form of semaglutide thats FDA-approved for type 2 diabetes but not yet for weight loss
It has been demonstrated that Zn(II) ions inhibit the activation of the NF-B factor, which is responsible for the expression of pro-inflammatory molecules such as IL-1, IL-6, IL-8, and TNF-, as well as pro-inflammatory enzymes like cyclooxygenases and nitric oxide synthase (Prasad 2014)
In the GHK-Cu formulation, it is specifically used to promote collagen and elastin synthesis, wound healing, reduction of inflammation, and cell renewal
Given this company's comms on their vision/plans, I am assuming there is a way that this approach might circumvent IP and marketing exclusivity
This article was reviewed and minor updates were made in February 2026.
The disease is heterogeneous and can be caused by different aspects such as microbial products, environmental triggers, or genetics